Epiomic Epidemiology Series Forecast Report on Multiple Myeloma in 18 Major Markets Multiple Myeloma is a cancer of plasma cells and is characterized by the production of abnormal immunoglobulins (Ig) or antibodies, as well as an accumulation of malignant plasma cells in the bone marrow. In some cases it can be asymptomatic, known as “smouldering” Multiple Myeloma. Although there have been several advancements in understanding how the disease develops, it is unclear as to what exactly causes it.
This report provides the current incident population for Multiple Myeloma across 18 Major Markets (USA, France, Germany, Italy, Spain, United Kingdom, Ireland, Brazil, Japan, India, Saudi Arabia, South Africa, Canada, Mexico, Turkey, Argentina, Russia and Australia) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of Multiple Myeloma have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Multiple Myeloma include:
• Anaemia
• Hypercalcaemia
• Increased % of bone marrow plasma cells (BMPC %)
• Thrombocytopenia
• Renal failure
• Elevated C-reactive protein
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Multiple Myeloma’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of Multiple Myeloma and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Multiple Myeloma’s incident population.
• Identify sub-populations within Multiple Myeloma which require treatment.
• Gain an understanding of the specific markets that have the largest number of Multiple Myeloma patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key Co-morbid Conditions/ Features Associated with the Disease
• Methodology for Quantification of Patient Numbers
• Top-Line Incidence for Multiple Myeloma (MM)
• Staging of Multiple Myeloma Patients
• Features of Multiple Myeloma Patients
o Histopathology classification of MM patients
o Severity of Bone Lesions in MM patients
o Type of Immunoglobulin / Monoclonal Protein Type in MM patients
• Co-morbid Conditions Associated with Multiple Myeloma
• Abbreviations used in the Report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• Durie-Salmon staging for MM
• International Staging System for MM
• Incidence of MM , total (000s)
• Incidence of MM, males (000s)
• Incidence of MM, females (000s)
• MM patients by stage – Durie-Salmon Staging system, total (000s)
• MM patients by stage – International Staging System, total (000s)
• Major Hystopathological types of MM patients, total (000s)
• Severity of bone lesions by type of MM patients, total (000s)
• Type of Ig / Monoclonal Proteins of MM patients, total (000s)
• Prevalence of Anaemia (<10g/dL) in MM patients, total (000s)
• Prevalence Renal Failure at diagnosis in MM patients, total (000s)
• Prevalence of BMPC ( ≥33 %) in MM patients, total (000s)
• Prevalence of Elevated C- reactive protein (≥ 0.8mg/dL) in MM patients, total (000s)
• Prevalence of Thrombocytopenia in MM patients, total (000s)
• Prevalence of Hypercalcaemia in MM patients, total (000s)
• Abbreviations and Acronyms used in the report
• USA Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• USA Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• France Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• France Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Germany Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Germany Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Italy Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Italy Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Spain Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Spain Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• UK Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• UK Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Ireland Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Ireland Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Japan Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Japan Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• India Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• India Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Saudi Arabia Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Saudi Arabia Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• South Africa Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• South Africa Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Canada Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Canada Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Mexico Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Mexico Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Turkey Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Turkey Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Australia Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Australia Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Argentina Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Argentina Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Russia Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Russia Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
• Brazil Incidence of Multiple Myeloma by 5-yr age cohort, males (000s)
• Brazil Incidence of Multiple Myeloma by 5-yr age cohort, females (000s)
